Patents Examined by Gary Nickol
-
Patent number: 9737574Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: February 5, 2016Date of Patent: August 22, 2017Assignee: Crestovo LLCInventor: Thomas Julius Borody
-
Patent number: 9725726Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.Type: GrantFiled: April 20, 2012Date of Patent: August 8, 2017Assignee: DANISCO US INCInventors: Elizabeth A. Bodie, Robert James Pratt, II
-
Patent number: 9719125Abstract: The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.Type: GrantFiled: April 5, 2016Date of Patent: August 1, 2017Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Manjiri T. Kshirsagar, Kurt J. Halverson, Neil Percy, James E. Aysta
-
Patent number: 9695229Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.Type: GrantFiled: August 21, 2014Date of Patent: July 4, 2017Assignee: The Regents of the University of Colorado, a body corporateInventor: Leland Shapiro
-
Patent number: 9696300Abstract: The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.Type: GrantFiled: September 1, 2015Date of Patent: July 4, 2017Assignee: ABAXIS, INC.Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Timothy P. Forsyth, Jeremy D. Walker, Cristina R. Cuesico
-
Patent number: 9688731Abstract: Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting Blastomyces dermatitidis infections in animals.Type: GrantFiled: December 19, 2012Date of Patent: June 27, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Bruce Klein, Theodore Brandhorst
-
Patent number: 9687514Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.Type: GrantFiled: February 1, 2013Date of Patent: June 27, 2017Assignee: Biocontrol LimitedInventors: James Soothill, Catherine Hawkins, David Harper
-
Patent number: 9687789Abstract: In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilizes ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of ultrafiltration. The ultrafiltration step is performed on an aqueous suspension of OMVs after they have been prepared from bacteria and the OMVs remain in suspension after the filtration step. The invention is particularly useful for preparing OMVs from Neisseria meningitidis.Type: GrantFiled: July 15, 2004Date of Patent: June 27, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Roberto Olivieri, Fabio Sabbatini, Ilio Marsili
-
Patent number: 9682108Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: September 8, 2016Date of Patent: June 20, 2017Assignee: Crestovo LLCInventor: Thomas Julius Borody
-
Patent number: 9675681Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.Type: GrantFiled: February 27, 2015Date of Patent: June 13, 2017Assignee: Wyeth LLCInventors: Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela S. Fink
-
Patent number: 9662380Abstract: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.Type: GrantFiled: January 29, 2015Date of Patent: May 30, 2017Assignee: Intervet Inc.Inventors: Huchappa Jayappa, Kevin O'Connell
-
Patent number: 9651546Abstract: The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.Type: GrantFiled: October 11, 2013Date of Patent: May 16, 2017Assignee: ABAXIS, INC.Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Timothy P. Forsyth, Jeremy D. Walker, Cristina R. Cuesico
-
Patent number: 9623056Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: September 7, 2016Date of Patent: April 18, 2017Assignee: Crestovo LLCInventor: Thomas Julius Borody
-
Patent number: 9611303Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid thatType: GrantFiled: March 18, 2015Date of Patent: April 4, 2017Assignee: JAPAN TOBACCO INC.Inventors: Yoshimitsu Takakura, Masako Tsunashima, Kozue Sofuku
-
Patent number: 9610308Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: June 9, 2016Date of Patent: April 4, 2017Assignee: Crestovo LLCInventor: Thomas Julius Borody
-
Patent number: 9610335Abstract: The invention relates to fusion proteins comprising an amino acid sequence of a fragment H corresponding to a fragment of a calcium binding protein excreted-secreted by adult worms of Fasciola hepatica, followed by an amino acid sequence corresponding to a unrelated protein or fragment of protein, pharmaceutical compositions, vaccines and adjuvants containing the immunogen, to a process for their preparation, another process for the production of antibodies and their use. The present invention relates to the preparation of immunogens by the addition of a peptide sequence. Thus the present invention is useful for producing an immune response, with increases in specific antibody titers in serum against proteins or other antigens and can be applied in particular for the production of specific polyclonal antibodies, immunotherapy and immunoprophylaxis.Type: GrantFiled: December 10, 2009Date of Patent: April 4, 2017Assignees: ESCOLA SUPERIOR AGRÁRIA DE COIMBRA, HITAG—BIOTECHNOLOGY, LDA.Inventors: Maria Antónia Pereira Da Conceição, Sofia Judite Marques Da Costa, António Manuel Oliveira Castro, André Augusto Da Silva Almeida
-
Patent number: 9599612Abstract: A label-free biochemical assay, in which label-free interrogation of a target-receptor layer is performed while the target-receptor layer is subjected to a relatively strong flow of an analyte-containing fluid. The volumetric flow rate for the assay is selected based on calibration data corresponding to the target substance, which advantageously results in fewer and/or smaller false-positive signals corresponding to non-target substances compared to those produced with the fluid being stationary. In various embodiments, the label-free interrogation method can be electro-mechanical and/or optical.Type: GrantFiled: February 25, 2010Date of Patent: March 21, 2017Assignee: Drexel UniversityInventors: Wan Y. Shih, Wei-Heng Shih, John-Paul McGovern
-
Patent number: 9599610Abstract: The invention generally relates to a system for isolating or separating a target from a sample. In certain aspects, processes performed by the target capture system include introducing a plurality of magnetic particles, in which a plurality of the particles include at least one binding moiety specific to a target, into a sample to form at least one target/particle complex and applying a magnetic field to isolate the magnetic particle/target complexes from the sample. The process starts at inputting a sample into the system and ends at delivering a capture target or nucleic acids of the target into a container for further analysis.Type: GrantFiled: December 16, 2013Date of Patent: March 21, 2017Assignee: DNAE Group Holdings LimitedInventors: Ravil A. Sitdikov, Eddie W. Adams, Magdalena A. Torrance, David K. Aley, Erik J. Smith, Victor C. Esch
-
Patent number: 9587284Abstract: The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum K37 strain, deposited in DSME-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH under Accession No. DSM 27445. The present invention further provides a pharmaceutical composition comprising the isolated lactic acid bacterium (Lactobacillus plantarum subsp. plantarum K37). Moreover, the present invention provides a method for preventing or treating a disorder in a subject, comprising a step of administering an effective amount of the isolated lactic acid bacterium (Lactobacillus plantarum subsp. plantarum K37) to the subject.Type: GrantFiled: February 21, 2014Date of Patent: March 7, 2017Assignee: Asian Probiotics and Prebiotics Ltd.Inventors: Ying-Chieh Tsai, Tan-Wei Liao, Yen-Wenn Liu, Yu-Han Chen, Chien-Chen Wu
-
Patent number: 9581589Abstract: The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample.Type: GrantFiled: December 1, 2009Date of Patent: February 28, 2017Assignee: ANDERSON FORSCHUNG GROUP LLCInventor: Norman L. Anderson